title: Should heart, lung, and liver transplant recipients receive immunosuppression induction for kidney transplantation?
abstract: As the outcomes of heart, liver, and lung transplantation continue to improve, more patients will present for subsequent renal transplantation. It remains unclear whether these patients benefit from induction immunosuppression. We retrospectively reviewed induction on solid organ graft recipients who underwent renal transplant at our center from January 1, 1995 to March 30, 2007. Induction and the non-induction groups were compared by univariate and Kaplan-Meier analyses. There were 21 patients in each group, with mean follow-up of 4.5-6.0 years. Forty-seven percent of patients receiving induction had a severe post-operative infection, compared with 28.6% in the non-induction group (p = NS). The one yr rejection rate in the induction group was 9.5% compared with 14.3% for non-induction (p = NS). One-yr graft survival was 81.0% and 95.2% in the induction and non-induction group (p = NS). In summary, there is a trend toward lower patient and graft survival among patients undergoing induction. These trends could relate to selection bias in the decision to prescribe induction immunosuppression, but further study is needed to better define the risks and benefits of antibody-induction regimens in this population.
authors.affiliation: Department of Surgery, Division of Transplantation, University of Michigan, Ann Arbor, MI, USA.
authors.forename: D N
authors.initials: DN
authors.lastname: Ranney
authors.forename: M J
authors.initials: MJ
authors.lastname: Englesbe
authors.forename: W
authors.initials: W
authors.lastname: Muhammad
authors.forename: S N
authors.initials: SN
authors.lastname: Al-Holou
authors.forename: J M
authors.initials: JM
authors.lastname: Park
authors.forename: S J
authors.initials: SJ
authors.lastname: Pelletier
authors.forename: J D
authors.initials: JD
authors.lastname: Punch
authors.forename: R J
authors.initials: RJ
authors.lastname: Lynch
mesh_terms: D000328:Adult; D015331:Cohort Studies; D005260:Female; D006085:Graft Survival; D006331:Heart Diseases / Q000150:complications / Q000276:immunology / Q000601:surgery; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000401:mortality / Q000601:surgery*; D008107:Liver Diseases / Q000150:complications / Q000276:immunology / Q000601:surgery; D008171:Lung Diseases / Q000150:complications / Q000276:immunology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D016377:Organ Transplantation; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents